Influence of inter-electrode distance on subthalamic nucleus local field potential recordings in Parkinson's disease

Clin Neurophysiol. 2022 Jan:133:29-38. doi: 10.1016/j.clinph.2021.10.003. Epub 2021 Oct 25.

Abstract

Objectives: To evaluate spectra and their correlations with clinical symptoms of local field potentials (LFP) acquired from wide- and close-spaced contacts (i.e. between contacts 0-3 or LFP03, and contacts 1-2 or LFP12 respectively) on the same DBS electrode within the subthalamus (STN) in Parkinson's disease (PD), before and after levodopa administration.

Methods: LFP12 and LFP03 were recorded from 20 PD patients. We evaluated oscillatory power, local and switched phase-amplitude coupling (l- and Sw-PAC) and correlation with motor symptoms (UPDRSIII).

Results: Before levodopa, both LFP03 and LFP12 power in the α band inversely correlated with UPDRSIII. Differences between contacts were found in the low-frequency bands power. After levodopa, differences in UPDRSIII were associated to changes in LFP03 low-β and LFP12 HFO (high frequency oscillations, 250-350 Hz) power, while a modulation of the low-β power and an increased β-LFO (low frequency oscillations, 15-45 Hz) PAC was found only for LFP12.

Conclusion: This study reveals differences in spectral pattern between LFP12 and LFP03 before and after levodopa administration, as well as different correlations with PD motor symptoms.

Significance: Differences between LFP12 and LFP03 may offer an opportunity for optimizing adaptive deep brain stimulation (aDBS) protocols for PD. LFP12 can be used to detect β-HFO coupling and β power (i.e. bradykinesia), while LFP03 are optimal for low frequency oscillations (dyskinesias).

Keywords: Deep brain stimulation; Levodopa; Local field potentials; Parkinson’s disease; Phase amplitude coupling; Subthalamic nucleus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiparkinson Agents / pharmacology
  • Antiparkinson Agents / therapeutic use
  • Deep Brain Stimulation
  • Electrodes, Implanted
  • Female
  • Humans
  • Levodopa / pharmacology
  • Levodopa / therapeutic use
  • Male
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology*
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology*
  • Subthalamic Nucleus / drug effects
  • Subthalamic Nucleus / physiopathology*

Substances

  • Antiparkinson Agents
  • Levodopa